FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307804902> ?p ?o ?g. }

• W4307804902 endingPage "A337" @default.
• W4307804902 startingPage "A337" @default.
• W4307804902 abstract "Abstract Objective Sodium-glucose cotransporter-2 (SGLT2) inhibitors are very effective in reducing hemoglobin A1c. They also have benefits in reducing cardiovascular events, heart failure hospitalization, and progression of renal disease in patients with and without T2DM. However, FDA issued a warning for a possible severe UTI. Conversely, the evidence from randomized clinical trials and observational studies is limited and controversial. Therefore, we aimed to investigate the association of urosepsis and SGLT-2 inhibitors using the method of systematic review and meta-analysis. Methods Potentially eligible studies were identified from MEDLINE, Scopus, EMBASE, Ovid, and the Cochrane Library from inception to September 2020 with the help of an experienced librarian aiming to identify studies reporting the number of adults users of any SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin, and tofogliflozin) who developed urosepsis, compared to those who never used SGLT2 inhibitors. The following exclusion criteria were used: only abstracts or pilot data, studies reporting rates of urosepsis only in SGLT2 inhibitors users without comparison, or studies with a comparison group in which SGLT2 was not the only differential treatment. Results In total, 1203 papers were identified with our search strategies, of which 169 were evaluated as full text, and 6 studies were finally selected for the meta-analysis after two rounds of the independent review by five investigators. The overall risk of bias of the included studies was low-to-moderate. We found no difference in the risk of urosepsis in users of SGLT2 inhibitors (OR= 1.34; 95% CI, 0.79 to 2.28; P=0.28; I2=48%) compared to the comparison group. In a subgroup analysis by the type of SGLT2 inhibitor evaluated we found no differences between dapagliflozin (OR= 0.92; 95% CI, 0.51 to 1.67; P=0.82; I2=0%) or canagliflozin (OR= 0.32; 95% CI, 0. 03 to 3.63; P=0.27; I2=17%) users in the risk of urosepsis. Publication bias was assessed by performing funnel plots which showed visual asymmetry suggestion potential publication bias. Discussion/Conclusion In this systematic review and meta-analysis, including 6 publications and 456301 participants, we found that individuals treated with SGLT2 inhibitors do not have a significantly higher risk of urosepsis than individuals of the comparison group. Additionally, no differences were found in the risk of urosepsis when each SLGT2 inhibitor agent was assessed separately. Presentation: No date and time listed" @default.
• W4307804902 created "2022-11-06" @default.
• W4307804902 creator A5003670445 @default.
• W4307804902 creator A5031078510 @default.
• W4307804902 creator A5048811007 @default.
• W4307804902 creator A5062310139 @default.
• W4307804902 creator A5068780125 @default.
• W4307804902 creator A5073635927 @default.
• W4307804902 date "2022-11-01" @default.
• W4307804902 modified "2023-10-14" @default.
• W4307804902 title "ODP252 Urosepsis and Sodium-Glucose Co-Transporter-2 Inhibitors: A Systematic Review and Meta-Analysis" @default.
• W4307804902 doi "https://doi.org/10.1210/jendso/bvac150.700" @default.
• W4307804902 hasPublicationYear "2022" @default.
• W4307804902 type Work @default.
• W4307804902 citedByCount "0" @default.
• W4307804902 crossrefType "journal-article" @default.
• W4307804902 hasAuthorship W4307804902A5003670445 @default.
• W4307804902 hasAuthorship W4307804902A5031078510 @default.
• W4307804902 hasAuthorship W4307804902A5048811007 @default.
• W4307804902 hasAuthorship W4307804902A5062310139 @default.
• W4307804902 hasAuthorship W4307804902A5068780125 @default.
• W4307804902 hasAuthorship W4307804902A5073635927 @default.
• W4307804902 hasBestOaLocation W43078049021 @default.
• W4307804902 hasConcept C126322002 @default.
• W4307804902 hasConcept C134018914 @default.
• W4307804902 hasConcept C168563851 @default.
• W4307804902 hasConcept C17744445 @default.
• W4307804902 hasConcept C177713679 @default.
• W4307804902 hasConcept C199539241 @default.
• W4307804902 hasConcept C23131810 @default.
• W4307804902 hasConcept C2775887513 @default.
• W4307804902 hasConcept C2776478404 @default.
• W4307804902 hasConcept C2777180221 @default.
• W4307804902 hasConcept C2777422806 @default.
• W4307804902 hasConcept C2777451236 @default.
• W4307804902 hasConcept C2779473830 @default.
• W4307804902 hasConcept C555293320 @default.
• W4307804902 hasConcept C71924100 @default.
• W4307804902 hasConcept C95190672 @default.
• W4307804902 hasConceptScore W4307804902C126322002 @default.
• W4307804902 hasConceptScore W4307804902C134018914 @default.
• W4307804902 hasConceptScore W4307804902C168563851 @default.
• W4307804902 hasConceptScore W4307804902C17744445 @default.
• W4307804902 hasConceptScore W4307804902C177713679 @default.
• W4307804902 hasConceptScore W4307804902C199539241 @default.
• W4307804902 hasConceptScore W4307804902C23131810 @default.
• W4307804902 hasConceptScore W4307804902C2775887513 @default.
• W4307804902 hasConceptScore W4307804902C2776478404 @default.
• W4307804902 hasConceptScore W4307804902C2777180221 @default.
• W4307804902 hasConceptScore W4307804902C2777422806 @default.
• W4307804902 hasConceptScore W4307804902C2777451236 @default.
• W4307804902 hasConceptScore W4307804902C2779473830 @default.
• W4307804902 hasConceptScore W4307804902C555293320 @default.
• W4307804902 hasConceptScore W4307804902C71924100 @default.
• W4307804902 hasConceptScore W4307804902C95190672 @default.
• W4307804902 hasIssue "Supplement_1" @default.
• W4307804902 hasLocation W43078049021 @default.
• W4307804902 hasLocation W43078049022 @default.
• W4307804902 hasOpenAccess W4307804902 @default.
• W4307804902 hasPrimaryLocation W43078049021 @default.
• W4307804902 hasRelatedWork W2151345870 @default.
• W4307804902 hasRelatedWork W2199901734 @default.
• W4307804902 hasRelatedWork W2807204184 @default.
• W4307804902 hasRelatedWork W2992022999 @default.
• W4307804902 hasRelatedWork W3081222781 @default.
• W4307804902 hasRelatedWork W3109685549 @default.
• W4307804902 hasRelatedWork W3118443349 @default.
• W4307804902 hasRelatedWork W4236245991 @default.
• W4307804902 hasRelatedWork W4306152306 @default.
• W4307804902 hasRelatedWork W4307804902 @default.
• W4307804902 hasVolume "6" @default.
• W4307804902 isParatext "false" @default.
• W4307804902 isRetracted "false" @default.
• W4307804902 workType "article" @default.